Israel · Delayed Price · Currency is ILS · Price in ILA BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of ILS 31.33 million. The enterprise value is 13.55 million.
| Market Cap | 31.33M |
| Enterprise Value | 13.55M |
Important Dates
The last earnings date was Monday, March 23, 2026.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.61 billion shares outstanding. The number of shares has increased by 105.76% in one year.
| Current Share Class | 2.61B |
| Shares Outstanding | 2.61B |
| Shares Change (YoY) | +105.76% |
| Shares Change (QoQ) | +2.12% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 3.97% |
| Float | 2.50B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.33 |
| PB Ratio | 0.42 |
| P/TBV Ratio | 5.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.62 |
| EV / Sales | 3.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.52 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.43.
| Current Ratio | 1.95 |
| Quick Ratio | 1.76 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.25 |
| Interest Coverage | -8.22 |
Financial Efficiency
Return on equity (ROE) is -11.01% and return on invested capital (ROIC) is -20.74%.
| Return on Equity (ROE) | -11.01% |
| Return on Assets (ROA) | -16.11% |
| Return on Invested Capital (ROIC) | -20.74% |
| Return on Capital Employed (ROCE) | -35.74% |
| Weighted Average Cost of Capital (WACC) | 8.34% |
| Revenue Per Employee | 170,993 |
| Profits Per Employee | -170,268 |
| Employee Count | 24 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.48, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 1.94 |
| Relative Strength Index (RSI) | 36.44 |
| Average Volume (20 Days) | 3,942,538 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLineRx had revenue of ILS 3.76 million and -3.75 million in losses. Loss per share was -0.00.
| Revenue | 3.76M |
| Gross Profit | 3.03M |
| Operating Income | -32.79M |
| Pretax Income | -6.46M |
| Net Income | -3.75M |
| EBITDA | -32.07M |
| EBIT | -32.79M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 66.55 million in cash and 32.36 million in debt, with a net cash position of 34.19 million or 0.01 per share.
| Cash & Cash Equivalents | 66.55M |
| Total Debt | 32.36M |
| Net Cash | 34.19M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 74.42M |
| Book Value Per Share | 0.02 |
| Working Capital | 36.85M |
Cash Flow
In the last 12 months, operating cash flow was -25.74 million and capital expenditures -79,700, giving a free cash flow of -25.82 million.
| Operating Cash Flow | -25.74M |
| Capital Expenditures | -79,700 |
| Depreciation & Amortization | 709,464 |
| Net Borrowing | -15.66M |
| Free Cash Flow | -25.82M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 80.51%, with operating and profit margins of -871.78% and -99.58%.
| Gross Margin | 80.51% |
| Operating Margin | -871.78% |
| Pretax Margin | -171.69% |
| Profit Margin | -99.58% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -105.76% |
| Shareholder Yield | -105.76% |
| Earnings Yield | -11.96% |
| FCF Yield | -82.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jun 7, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
BioLineRx has an Altman Z-Score of -13.64 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.64 |
| Piotroski F-Score | 3 |